Overview: Free Estradiol (Free E2) TestIntroduction: The Free Estradiol (Free E2) Test measures free estradiol to assess hormonal disorders, causing infertility or menopausal symptoms. Following 2023 Endocrine Society guidelines, it uses an immunoassay for high sensitivity, aiding in endocrine screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in endocrinology for patients with suspected hormonal imbalances.
Other Names: Free E2 Assay, Unbound Estradiol Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: Free estradiol testing began in the 1980s with hormone research. Advanced immunoassays emerged in the 2000s, improving accuracy for unbound hormone measurement.
Purpose: Diagnoses hormonal disorders, guides treatment, and monitors free estradiol levels in patients with infertility or menopausal symptoms.
Test Parameters: 1. Free Estradiol
Pretest Condition: Fasting for 10-12 hours required to stabilize hormone levels. Collect serum or plasma in the morning. Report symptoms like infertility or menopausal symptoms, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document infertility, menopausal symptoms, or history of hormonal disorders. Include current medications, especially hormonal therapies.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for hormonal therapy.
Procedural Considerations: Uses an immunoassay to measure free estradiol levels. Results are available in 3-5 days, enabling clinical decisions.
Factors Affecting Result Accuracy: Non-fasting, stress, or medications can affect results. Hemolysis may degrade samples.
Clinical Significance: Abnormal free estradiol levels suggest hormonal disorders (e.g., menopause, PCOS), prompting treatment. Normal levels may require further testing.
Specialist Consultation: Consult an endocrinologist or reproductive specialist for result interpretation.
Additional Supporting Tests: Total estradiol, FSH, or pelvic ultrasound to confirm hormonal disorders.
Test Limitations: Results may be affected by medications or stress. Clinical correlation is required.
References: Endocrine Society Hormone Guidelines, 2023; Journal of Clinical Endocrinology, Stanczyk FZ, 2022.
